Effective Feedback to Improve Primary Care Prescribing Safety

Not Applicable

Completed

• Conditions: Complications of Surgical and Medical Care: General Terms
• Interventions: Other: Usual care; Other: Feedback of Performance + Health Psychology Informed Intervention; Other: Feedback of Performance

• Registration Number: NCT01602705
• Lead Sponsor: University of Dundee

Brief Summary

We hypothesise that feedback and feedback + psychology informed intervention delivered to primary care medical practices will reduce high-risk prescribing to patients compared to a simple educational intervention alone. The specific objectives are :

1. To test the effectiveness of the two EFIPPS feedback arms in reducing the specified primary outcome of a composite measure of high-risk antipsychotic, non-steroidal anti-inflammatory drug, and antiplatelet drug prescribing

2. To test the effectiveness of the two EFIPPS feedback arms in reducing the specified secondary outcomes of the six individual measures constituting the composite

3. To assess the cost-effectiveness of the intervention

Detailed Description

High risk prescribing is the use of drugs which carry significant risk to patients. Such prescribing is not always inappropriate but does require regular review to ensure that the balance of risk and benefit in individuals is appropriate. High risk prescribing is common and varies widely between practices, and there is evidence that intensive interventions (for example, pharmacist led medication review) can reduce rates of high risk prescribing. The aim of this study is to test whether a simpler and therefore cheaper feedback intervention can reduce high risk prescribing. The study is a three arm cluster randomised trial with primary care medical practices as the unit of randomisation and outcomes measured at patient level using routinely held prescribing for individual patients. The trial will compare two forms of feedback of practice rates of high risk prescribing with usual care. Usual care matches existing NHS working practice. The first active arm will receive quarterly feedback. The second active arm will receive the same feedback plus a health psychology informed intervention designed to promote response to feedback embedded in the feedback.

Study Timeline

• Study First Submitted: 2012-05-17
• Study First Submitted QC: 2012-05-17
• Study First Posted: 2012-05-21
• Study Start: 2012-06
• Primary Completion: 2013-10
• Study Completion: 2013-10
• Status Verified: 2014-10
• Last Update Submitted: 2014-10-05
• Last Update Posted: 2014-10-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 262

Inclusion Criteria

• General medical practices in NHS Ayrshire and Arran, NHS Lanarkshire and NHS Lothian

Exclusion Criteria

• Practices with <250 registered patients
• Practices with <93% of scripts in the new PIS data warehouse having a unique patient identifier (the Community Health Index [CHI] number)
• Practices which were formed after 1st January 2011
• Practices which cease to exist during the trial
• Practices which merge during the trial, where the merging practices were originally in different arms of the trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Usual care	Usual care	-
Usual care + feedback + health psychology intervention	Feedback of Performance + Health Psychology Informed Intervention	-
Usual care + feedback of practice performance	Feedback of Performance	-

Primary Outcome Measures

Name	Time	Method
Composite measure of proportion of patients at risk of an adverse event from specified prescribing.	Change in proportion of patients prescribed a high risk drug between baseline and 12 months after the intervention	The primary outcome is a composite of six high-risk prescribing measures relating to antipsychotic, non-steroidal anti-inflammatory and antiplatelet drug use. It is defined as the proportion of patients particularly at risk of an adverse event from the specified prescribing, who receives one or more high risk prescriptions. A composite is reasonable because each of the underlying indicators is based on evidence of harm and has been judged valid in one or more formal consensus studies, so the composite is a coherent measure of 'high-risk prescribing'.

Trial Locations

Locations (1)

NHS National Services Scotland; 🇬🇧 Edinburgh, United Kingdom